Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: Results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial

Journal of Clinical Oncology

Volumn 30, Issue 36, 2012, Pages 4501-4507

  Ardizzoni, Andrea ^a   Tiseo, Marcello ^a   Boni, Luca ^b   Vincent, Andrew D ^s   Passalacqua, Rodolfo ^c   Buti, Sebastiano ^c   Amoroso, Domenico ^d   Camerini, Andrea ^d   Labianca, Roberto ^e   Genestreti, Giovenzio ^f   Boni, Corrado ^g   Ciuffreda, Libero ^h   Di Costanzo, Francesco ^b   De Marinis, Filippo ⁱ   Crinò, Lucio ^j   Santo, Antonio ^k   Pazzola, Antonio ^l   Barbieri, Fausto ^m   Zilembo, Nicoletta ⁿ   Colantonio, Ida ^o   Tibaldi, Carmelo ^p   Mattioli, Rodolfo ^q   Cafferata, Mara A ^r   Camisa, Roberta ^a   Smit, Egbert F ^t   more..

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c Ospedale Civile   (Italy)

^d Ospedale Della Versilia   (Italy)

^e OSPEDALI RIUNITI   (Italy)

^f ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^g S MARIA NUOVA HOSPITAL   (Italy)

^h MOLINETTE HOSPITAL   (Italy)

ⁱ SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^j UNIVERSITY OF PERUGIA   (Italy)

^k Azienda Ospedaliero Universitaria   (Italy)

^l SS Annunziata Hospital   (Italy)

^m Azienda Ospedaliero Universitaria   (Italy)

ⁿ NATIONAL CANCER INSTITUTE   (Italy)

^o S CROCE E CARLE HOSPITAL   (Italy)

^p Azienda USL 6 di Livorno   (Italy)

^q Ospedale di Fano   (Italy)

^r GALLIERA HOSPITAL   (Italy)

^s NETHERLANDS CANCER INSTITUTE   (Netherlands)

^t VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 84871737387     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.6758     Document Type: Article

References (31)

1. [No authors listed]: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials - Non-Small Cell Lung Cancer Collaborative Group. BMJ 311:899-909, 1995
2. Azzoli CG, Baker S Jr, Temin S, et al: American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251-6266, 2009
3. Delbaldo C, Michiels S, Syz N, et al: Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis. JAMA 292:470-484, 2004
4. Rosso R, Salvati F, Ardizzoni A, et al: Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer: Results of a prospective randomized FONICAP (Italian Lung Cancer Task Force) trial - Italian Lung Cancer Task Force. Cancer 66:130-134, 1990
5. Splinter TA, Sahmoud T, Festen J, et al: Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: A randomized study of the European Organisation for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14:127-134, 1996
6. Kosmidis PA, Dimopoulos MA, Syrigos K, et al: Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: A prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol 2:135-140, 2007
7. Gridelli C, Ardizzoni A, Ciardiello F, et al: Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol 3:430-440, 2008
8. Ardizzoni A, Tiseo M: Second-line chemotherapy in the treatment of advanced non-small lung cancer (NSCLC). J Chemother 16:104-107, 2004 (suppl 4)
9. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
10. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354-2362, 2000
11. Smit EF, Mattson K, von Pawel J, et al: ALIMTA (pemetrexed disodium) as second line treatment of non-small cell lung cancer: A phase II study. Ann Oncol 14:455-460, 2003
12. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004
13. de Marinis F, Pereira JR, Fossella F, et al: Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: An analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol 3:30-36, 2008
14. Georgoulias V, Kouroussis C, Agelidou A, et al: Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: A multicentre, randomised, phase II study. Br J Cancer 91:482-488, 2004
15. Georgoulias V, Agelidou A, Syrigos K, et al: Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: A multicenter randomized phase II study. Br J Cancer 93:763-769, 2005
16. Wachters FM, Groen HJ, Biesma B, et al: A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer 92:15-20, 2005
17. Pectasides D, Pectasides M, Farmakis D, et al: Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: A randomized phase II trial. Ann Oncol 16:294-299, 2005
18. Fossella FV: Pemetrexed for treatment of advanced non-small cell lung cancer. Semin Oncol 31:100-105, 2004 (suppl 1)
19. Hughes A, Calvert P, Azzabi A, et al: Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20:3533-3544, 2002
20. Zinner RG, Fossella FV, Gladish GW, et al: Phase II study of pemetrexed in combination with carboplatin in the first line treatment of advanced non-small cell lung cancer. Cancer 104:2449-2456, 2005
21. Scagliotti G, Kortsik C, Dark GG, et al: Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial. Clin Cancer Res 11:690-696, 2005
22. Smit EF, Burgers SA, Biesma B, et al: Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 27:2038-2045, 2009
23. Takeda K, Negoro S, Tamura T, et al: Phase III trail of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: Results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 20:835-841, 2009
24. Gebbia V, Gridelli C, Verusio C, et al: Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients: The DISTAL-2 randomized trial. Lung Cancer 63:251-258, 2009
25. Di Maio M, Chiodini P, Georgoulias V, et al: Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 27:1836-1843, 2009
26. de Lima Araújo LH, Ferreira CG: Platinum-based second-line treatment in non-small-cell lung cancer: An old new kid on the block? J Clin Oncol 28:e24-e25, 2010; author reply e26
27. Tiseo M, Ardizzoni A: Current status of second-line treatment and novel therapies for small cell lung cancer. J Thorac Oncol 2:764-772, 2007
28. Ledermann JA, Kristeleit RS: Optimal treatment for relapsing ovarian cancer. Ann Oncol 21:vii218-vii222, 2010 (suppl 7)
29. Scagliotti G, Brodowicz T, Shepherd FA, et al: Treatment-by-histology interaction analysis in three phase III trias show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 6:64-70, 2011
30. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
31. Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 374:1432-1440, 2009